China’s pharmaceutical packaging industry is becoming more sophisticated as pharmaceutical manufacturing shifts toward biologics, injectables, vaccines, generics and advanced drug-delivery systems. 

According to Towards Healthcare Research and Consulting, china's pharmaceutical packaging market is estimated at $22.40 billion in 2026, up from $21.13 billion in 2025, and is projected to reach $30.08 billion by 2031, representing a 6.04% CAGR.

Ready-to-use (RTU) packaging is gaining attention because pre-sterilized vials, syringes, cartridges and other components can reduce preparation steps before filling and support more controlled pharmaceutical manufacturing.

Role of RTU Packaging in China

RTU packaging can reduce the need for on-site washing, depyrogenation and sterilization of individual components, helping manufacturers simplify sterile filling operations.

This is particularly relevant for biologics and injectable drugs, where contamination control and container integrity are critical. China’s pharmaceutical industry reached approximately RMB 2.97 trillion in 2024, creating a large manufacturing base for advanced packaging solutions.

Latest Technologies Used

Chinese manufacturers are increasingly using pre-sterilized glass and polymer containers, ready-to-fill syringes, blow-fill-seal (BFS), automated filling, robotic component handling and machine-vision inspection.

Other technologies include serialization, track-and-trace, high-barrier materials and low-extractable/low-leachable packaging for sensitive medicines. Automation is becoming increasingly important as manufacturers seek higher throughput and consistent quality.

Which Region Is Dominating?

East China remains a major pharmaceutical manufacturing and packaging cluster, particularly across Shanghai, Jiangsu and Zhejiang. The region benefits from pharmaceutical manufacturing capacity, biotechnology activity, suppliers and logistics infrastructure.

Jiangsu is particularly significant for biopharmaceutical development. In 2025, China-headquartered sponsors conducted 32% of global clinical trials, up from only 2% in 2009, highlighting the country's expanding drug-development ecosystem.

How China Differs From Other Countries

China combines large-scale pharmaceutical production, domestic manufacturing capabilities and cost-efficient supply chains with rapidly developing automation and biotechnology infrastructure.

Unlike more mature Western markets, China's packaging sector is simultaneously expanding basic pharmaceutical packaging capacity and moving toward sterile RTU formats, automation, smart packaging and higher-performance materials.

Job Opportunities

The expansion creates opportunities beyond packaging production. Potential roles include pharmaceutical packaging engineer, validation specialist, quality-control analyst, sterile manufacturing specialist, packaging R&D scientist, regulatory-affairs professional, automation engineer and supply-chain specialist.

Demand is also emerging for professionals who understand global regulatory requirements, biologics manufacturing and international pharmaceutical operations. Reuters reported in 2026 that Chinese drugmakers are facing shortages of internationally experienced professionals as their global activities expand. 

Reference: https://www.towardshealthcare.com/insights/ready-to-use-pharmaceutical-packaging-market-sizing